- Email: [email protected]
MIT professor elected to Ionics board
News & Views
s u b - p i c o m o l a r sensitivity, Dr Cornell equated it to "detecting the s u g a r c o n t e n t of S y d n e y H a r b o u r after throwing a s u g a r cube from a felTy". Additionally, in t e r m s of compatibility with microelectronics, the CRCMET t e a m indicate t h a t the direct electrical o u t p u t offered by the new device h a s significant a d v a n t a g e s over the optical o u t p u t of previous biosensors. The b i o s e n s o r h a s a large n u m b e r of potential a p p l i c a t i o n s which can be applied to complex m e d i a s u c h as blood. Applications include the detection of viruses, DNA (gene sequences), drugs, h o r m o n e s , a n t i b o d i e s a n d pesticides. According to the CRC-MET t e a m the b i o s e n s o r h a s been o p e r a t i n g s u c c e s s f u l l y for several m o n t h s in the l a b o r a t o r y a n d the first commercial p r o d u c t s are expected to be l a u n c h e d within the next two years.
For further information contact: Dr Bruce Cornell, CSIRO, The University of Sydney, NSW, S y d n e y 2052, Australia. Tel: +61 2 9422 3195; lnternet: http: / / www.ambri.com.au.
M e m t e c third quarter earnings US$2.2M Memtec have r e p o r t e d t h a t e a r n i n g s for the third q u a r t e r of fiscal 1997 were US$2.2 million or US80.22 p e r s h a r e - - in line with m a r k e t expectations. Net sales for the three months ended March 31, 1997 i n c r e a s e d 40% to US$59.0 million c o m p a r e d with US$42.0 million for the third q u a r t e r of fiscal 1996. Net sales for the nine m o n t h s ended 31 March, 1997 i n c r e a s e d 50% to US8176.0 million c o m p a r e d with US$117.0 million for the first three quarters of fiscal 1996. Operating profit for the three months ended March 31, 1997 increased 60% to US$11.5 million compared with US$7.2 million for the first three quarters of fiscal 1996. Income before taxes for the three m o n t h s ended March 31, 1997 i n c r e a s e d 10% to US$3.1 million c o m p a r e d with US$2.8 million for the third q u a r t e r of fiscal 1996. Income before taxes for the nine m o n t h s ended March 31, 1997 increased 52% to US$8.0 million compared,with US$5.2 million for the first three quarters of fiscal 1996. The net income of US$2.2 million for the first three m o n t h s ended March 31, 1997 was c o m p a r a b l e to the n e t income of US$2.3 million for the s a m e period in 1996. Net income for the nine m o n t h s ended March 31, 1997 was US$6.8 million (US$0.66 per share) c o m p a r e d with USS8.0 million (US$0.88 per share) for the nine m o n t h s ended March 31 1996. This c o m p a r i s o n h a s b e e n affected by a USS0.47 tax benefit b o o k e d in the second q u a r t e r of fiscal 1996. Backlog at March 31, 1997 i n c r e a s e d 3% to US$67 million c o m p a r e d with March 31, 1996. Filterite b a c k l o g i n c r e a s e d 6% to USS6 million, Fluid d y n a m i c s b a c k l o g d e c r e a s e d 34% to US824 million, Memcor backlog i n c r e a s e d 34% to US833 million a n d Seitz backlog w a s USS5 million.
2
For further information contact: Memtec Ltd, 1 Memtec Parkway, Windsor, N S W 2756, Australia. Tel: +61 45 77 6800;fax: +61 45 77 6804. Internet: http: / / www.memtec.com.
MIT professor e l e c t e d to Ionics board Ionics s h a r e h o l d e r s elected Dr Daniel I.C. Wang to the b o a r d of directors at the c o m p a n y ' s r e c e n t a n n u a l meeting. Dr Wang is Institute Professor at the M a s s a c h u s e t t s Institute of Technology as well as Chevron Professor of Chemical Engineering a n d Director of the Biotechnology Process Engineering Center. A r t h u r L. Goldstein, Ionics' C h a i r m a n a n d Chief Executive Officer, c o m m e n t e d "we are delighted with Dr Wang's election. He b r i n g s a u n i q u e c o m b i n a t i o n of technology a n d b u s i n e s s experience to Ionics. In addition to his chemical engineering expertise which c o m p l e m e n t s the C o m p a n y ' s work in s e p a r a t i o n s technology, Dr Wang brings extensive knowledge of the F a r East, p a r t i c u l a r l y in a p p l i c a t i o n s a n d m a r k e t s in which the C o m p a n y h a s recently b e c o m e engaged."
For further information contact: Ionics Inc., P.O. Box 9131, Watertown, MA 02272-9131, USA. Tel: +1 617 926 2500;fax: +1 617 926 4304. http: / / w w w . ionics, com.
Pall wins Queen's award It was recently a n n o u n c e d t h a t Pall E u r o p e Ltd, the P o r t s m o u t h (UK) b a s e d m a n u f a c t u r e r of high technology filters a n d filtration e q u i p m e n t , h a s again been awarded the Queen's Award for Export Achievement. The C o m p a n y won the Award in 1987 a n d in 1992. Pall E u r o p e h a s won the Award, which is conferred a n n u a l l y on only a small n u m b e r of British companies, as a r e s u l t of its consistently high level of export achievement. During the l a s t ten y e a r s , export sales, as a p e r c e n t a g e of total turnover, averaged 71%, whilst total export sales have grown 375% since 1987. The Company' s m a i n export m a r k e t s are W e s t e r n a n d E a s t e r n Europe, the Middle East, Africa, India, P a k i s t a n a n d A u s t r a l a s i a . In its overseas m a r k e t s , Pall h a s e s t a b l i s h e d s u c c e s s f u l selling c o m p a n i e s in Austria, France, G e r m a n y , Italy, Poland, S p a i n a n d Switzerland, and new J o i n t Ventures in India a n d Russia. Combined with local sales offices in other countries, Pall c u r r e n t l y employs over 900 people who are r e s i d e n t in its overseas m a r k e t s .
M e m b r a n e T e c h n o l o g y No. 8 5
s u b - p i c o m o l a r sensitivity, Dr Cornell equated it to "detecting the s u g a r c o n t e n t of S y d n e y H a r b o u r after throwing a s u g a r cube from a felTy". Additionally, in t e r m s of compatibility with microelectronics, the CRCMET t e a m indicate t h a t the direct electrical o u t p u t offered by the new device h a s significant a d v a n t a g e s over the optical o u t p u t of previous biosensors. The b i o s e n s o r h a s a large n u m b e r of potential a p p l i c a t i o n s which can be applied to complex m e d i a s u c h as blood. Applications include the detection of viruses, DNA (gene sequences), drugs, h o r m o n e s , a n t i b o d i e s a n d pesticides. According to the CRC-MET t e a m the b i o s e n s o r h a s been o p e r a t i n g s u c c e s s f u l l y for several m o n t h s in the l a b o r a t o r y a n d the first commercial p r o d u c t s are expected to be l a u n c h e d within the next two years.
For further information contact: Dr Bruce Cornell, CSIRO, The University of Sydney, NSW, S y d n e y 2052, Australia. Tel: +61 2 9422 3195; lnternet: http: / / www.ambri.com.au.
M e m t e c third quarter earnings US$2.2M Memtec have r e p o r t e d t h a t e a r n i n g s for the third q u a r t e r of fiscal 1997 were US$2.2 million or US80.22 p e r s h a r e - - in line with m a r k e t expectations. Net sales for the three months ended March 31, 1997 i n c r e a s e d 40% to US$59.0 million c o m p a r e d with US$42.0 million for the third q u a r t e r of fiscal 1996. Net sales for the nine m o n t h s ended 31 March, 1997 i n c r e a s e d 50% to US8176.0 million c o m p a r e d with US$117.0 million for the first three quarters of fiscal 1996. Operating profit for the three months ended March 31, 1997 increased 60% to US$11.5 million compared with US$7.2 million for the first three quarters of fiscal 1996. Income before taxes for the three m o n t h s ended March 31, 1997 i n c r e a s e d 10% to US$3.1 million c o m p a r e d with US$2.8 million for the third q u a r t e r of fiscal 1996. Income before taxes for the nine m o n t h s ended March 31, 1997 increased 52% to US$8.0 million compared,with US$5.2 million for the first three quarters of fiscal 1996. The net income of US$2.2 million for the first three m o n t h s ended March 31, 1997 was c o m p a r a b l e to the n e t income of US$2.3 million for the s a m e period in 1996. Net income for the nine m o n t h s ended March 31, 1997 was US$6.8 million (US$0.66 per share) c o m p a r e d with USS8.0 million (US$0.88 per share) for the nine m o n t h s ended March 31 1996. This c o m p a r i s o n h a s b e e n affected by a USS0.47 tax benefit b o o k e d in the second q u a r t e r of fiscal 1996. Backlog at March 31, 1997 i n c r e a s e d 3% to US$67 million c o m p a r e d with March 31, 1996. Filterite b a c k l o g i n c r e a s e d 6% to USS6 million, Fluid d y n a m i c s b a c k l o g d e c r e a s e d 34% to US824 million, Memcor backlog i n c r e a s e d 34% to US833 million a n d Seitz backlog w a s USS5 million.
2
For further information contact: Memtec Ltd, 1 Memtec Parkway, Windsor, N S W 2756, Australia. Tel: +61 45 77 6800;fax: +61 45 77 6804. Internet: http: / / www.memtec.com.
MIT professor e l e c t e d to Ionics board Ionics s h a r e h o l d e r s elected Dr Daniel I.C. Wang to the b o a r d of directors at the c o m p a n y ' s r e c e n t a n n u a l meeting. Dr Wang is Institute Professor at the M a s s a c h u s e t t s Institute of Technology as well as Chevron Professor of Chemical Engineering a n d Director of the Biotechnology Process Engineering Center. A r t h u r L. Goldstein, Ionics' C h a i r m a n a n d Chief Executive Officer, c o m m e n t e d "we are delighted with Dr Wang's election. He b r i n g s a u n i q u e c o m b i n a t i o n of technology a n d b u s i n e s s experience to Ionics. In addition to his chemical engineering expertise which c o m p l e m e n t s the C o m p a n y ' s work in s e p a r a t i o n s technology, Dr Wang brings extensive knowledge of the F a r East, p a r t i c u l a r l y in a p p l i c a t i o n s a n d m a r k e t s in which the C o m p a n y h a s recently b e c o m e engaged."
For further information contact: Ionics Inc., P.O. Box 9131, Watertown, MA 02272-9131, USA. Tel: +1 617 926 2500;fax: +1 617 926 4304. http: / / w w w . ionics, com.
Pall wins Queen's award It was recently a n n o u n c e d t h a t Pall E u r o p e Ltd, the P o r t s m o u t h (UK) b a s e d m a n u f a c t u r e r of high technology filters a n d filtration e q u i p m e n t , h a s again been awarded the Queen's Award for Export Achievement. The C o m p a n y won the Award in 1987 a n d in 1992. Pall E u r o p e h a s won the Award, which is conferred a n n u a l l y on only a small n u m b e r of British companies, as a r e s u l t of its consistently high level of export achievement. During the l a s t ten y e a r s , export sales, as a p e r c e n t a g e of total turnover, averaged 71%, whilst total export sales have grown 375% since 1987. The Company' s m a i n export m a r k e t s are W e s t e r n a n d E a s t e r n Europe, the Middle East, Africa, India, P a k i s t a n a n d A u s t r a l a s i a . In its overseas m a r k e t s , Pall h a s e s t a b l i s h e d s u c c e s s f u l selling c o m p a n i e s in Austria, France, G e r m a n y , Italy, Poland, S p a i n a n d Switzerland, and new J o i n t Ventures in India a n d Russia. Combined with local sales offices in other countries, Pall c u r r e n t l y employs over 900 people who are r e s i d e n t in its overseas m a r k e t s .
M e m b r a n e T e c h n o l o g y No. 8 5